Cite
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study
MLA
Camillo Porta, et al. Sorafenib Dose Escalation in Treatment-Naïve Patients with Metastatic Renal Cell Carcinoma: A Non-Randomised, Open-Label, Phase 2b Study. June 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b164caf0a3105d8373b3646cb0ded14f&authtype=sso&custid=ns315887.
APA
Camillo Porta, Tomasz Demkow, Alessandra Bearz, Martin Gore, Jo Ann Shapiro, Robert Jones, Alain Ravaud, Uwe Phillip Strauss, & Markus A. Kuczyk. (2017). Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
Chicago
Camillo Porta, Tomasz Demkow, Alessandra Bearz, Martin Gore, Jo Ann Shapiro, Robert Jones, Alain Ravaud, Uwe Phillip Strauss, and Markus A. Kuczyk. 2017. “Sorafenib Dose Escalation in Treatment-Naïve Patients with Metastatic Renal Cell Carcinoma: A Non-Randomised, Open-Label, Phase 2b Study,” June. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b164caf0a3105d8373b3646cb0ded14f&authtype=sso&custid=ns315887.